Neuroimmunologist Bruce Cree, MD, provides a detailed overview of ublituximab as an anti-CD20 therapy, including its mechanism of B-cell depletion, differentiation from other agents in the class, and the clinical trial pathway that led to its approval in relapsing MS.
An in-depth analysis of 5-year ULTIMATE open-label extension data, highlighting sustained relapse reduction, disability outcomes, and the long-term impact of early ublituximab initiation in relapsing MS.
A comprehensive review of long-term safety findings with ublituximab, including infection risk, immunoglobulin trends, and tolerability over 5 years, with context on how these data inform ongoing treatment decisions in relapsing MS.
A forward-looking discussion on how real-world experience is shaping the use of ublituximab, including patient selection, infusion logistics, monitoring strategies, and emerging considerations such as subcutaneous development and long-term safety management.
